PORTFOLIO PRESS RELEASE
GlyTech, Inc. concluded a joint development agreement on “sugar chain modified somatostatin analog” with NIPPON SHOKUBAI CO., LTD. and implemented capital alliance.
NIPPON SHOKUBAI CO., LTD. and GlyTech, Inc. agreed to jointly develop “sugar chain modified somatostatin analog” jointly. NIPPON SHOKUBAI agreed on October 8, 2015 to invest in the peptide drug discovery research facility.
For the details, please see the news release of GlyTech, Inc.